Zacks Investment Research upgraded shares of Yield10 Bioscience (NASDAQ:YTEN) from a hold rating to a buy rating in a report released on Wednesday, Zacks.com reports. They currently have $13.00 price objective on the specialty chemicals company’s stock.
According to Zacks, “Yield10 Bioscience, Inc. is an agricultural bioscience company. It focuses on the development of disruptive technologies for improvement in crop yield to enhance global food security. The company is working on new approaches, to improve fundamental elements of plant photosynthetic efficiency and optimizing carbon metabolism for better production. It operates primarily in Saskatoon, Saskatchewan, Canada. Yield10 Bioscience, Inc., formerly known as Metabolix, Inc., is based in Woburn, Massachusetts. “
Separately, Maxim Group boosted their target price on shares of Yield10 Bioscience from $12.00 to $24.00 and gave the stock a buy rating in a research report on Tuesday, February 9th.
Yield10 Bioscience (NASDAQ:YTEN) last issued its quarterly earnings data on Monday, March 15th. The specialty chemicals company reported ($0.79) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.70) by ($0.09). Yield10 Bioscience had a negative return on equity of 347.89% and a negative net margin of 1,861.39%. On average, equities research analysts anticipate that Yield10 Bioscience will post -4.78 EPS for the current year.
In other Yield10 Bioscience news, major shareholder Jack W. Schuler purchased 101,400 shares of the stock in a transaction on Wednesday, February 3rd. The shares were purchased at an average price of $12.25 per share, with a total value of $1,242,150.00. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Insiders own 1.90% of the company’s stock.
An institutional investor recently raised its position in Yield10 Bioscience stock. Cannell Peter B & Co. Inc. lifted its position in Yield10 Bioscience, Inc. (NASDAQ:YTEN) by 55.3% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 144,625 shares of the specialty chemicals company’s stock after purchasing an additional 51,500 shares during the quarter. Cannell Peter B & Co. Inc. owned 3.14% of Yield10 Bioscience worth $836,000 at the end of the most recent reporting period. 6.08% of the stock is currently owned by hedge funds and other institutional investors.
Yield10 Bioscience Company Profile
Yield10 Bioscience, Inc, an agricultural bioscience company, engages in developing disruptive technologies for step-changing improvements in crop yield in the United States and Canada. The company, through its Trait Factory, is involved in developing high value seed traits for the agriculture and food industries.
Featured Story: Google Finance Portfolio
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Yield10 Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Yield10 Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.